Replies to post #156609 on Biotech Values

[DewDiligence]

Agreed—GILD will have two distinct Sofosbuvir NDA filings: one with GS-5885 and one without; however, the timing of the two FDA reviews may overlap, and I was speaking about the composite outcome when I mentioned the possibility of a label excluding genotype-3.

p.s. My prior post was badly written, and oc631 made the same point you did via a private message. It’s good to have posters on the board who are on the ball to the degree that the two of you are!